Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $175.00 short put and a strike $165.00 long put offers a potential 22.4% return on risk over the next 38 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $175.00 by expiration. The full premium credit of $1.83 would be kept by the premium seller. The risk of $8.17 would be incurred if the stock dropped below the $165.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.
The RSI indicator is at 75.14 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Amgen Tops Heart Study As Rivals Regeneron, Sanofi Chill In Court
Mon, 13 Mar 2017 20:37:51 GMT
Amgen's Repatha lowers need for cholesterol-lowering procedure
Mon, 13 Mar 2017 13:24:53 GMT
Amgen says its Repatha reduced need for high cholesterol therapy in late-stage clinical trial
Mon, 13 Mar 2017 13:20:38 GMT
9:03 am Amgen announces its Phase 3 study evaluating Repatha met its primary endpoint
Mon, 13 Mar 2017 13:03:00 GMT
Repatha® (Evolocumab) Demonstrates Reduced Need For Apheresis In Patients With High LDL Cholesterol In Phase 3 Study
Mon, 13 Mar 2017 13:00:00 GMT
PR Newswire – THOUSAND OAKS, Calif., March 13, 2017 /PRNewswire/ — Amgen (AMGN) today announced positive top-line results from a Phase 3 study evaluating Repatha® (evolocumab) in patients who were receiving apheresis to reduce low-density lipoprotein cholesterol (LDL-C). The study met its primary endpoint, demonstrating that treatment with Repatha significantly reduced the need for LDL-C apheresis in adult patients, as measured at the end of the randomized period. The study also met its secondary endpoints of percent change from baseline to week 4 in LDL-C, non-high-density lipoprotein cholesterol (non-HDL-C) and total cholesterol:HDL-C ratio.
Also on Market Tamer…
Follow Us on Facebook